The general poor prognosis of AML has stimulated the haematology society and industry to move forward in recent years. Because of these efforts, you could easily imagine yourself at a myeloma session during EHA2021. For patients non-eligible for intensive chemotherapy, the therapeutic arsenal has never been so wide and is constantly expanding. In Belgium, haematologists are bound to strict regulations making ‘game-changing’ data scarce at international congresses. However, the experts in the field shared their strategies in daily practice, which might be even more useful. Nevertheless, one rule remains that it is our duty to include patients in clinical trials whenever possible.

(BELG J HEMATOL 2021;12(5):197-200)